Introduction
> Primary cutaneous T-cell lymphoma (CTCL) is a rare class of non-Hodgkin's lymphoma that originates in the skin. > Single-agent romidepsin induces apoptotic events in cancer cells by inhibiting histone deactylase (HDAC) enzymes. > A Phase II trial of romidepsin monotherapy has shown clinical benefit in patients (pts) with CTCL (JCO 2009; 27:5410 > Pralatrexate shows impressive clinical activity in patients with relapsed or refractory CTCL at a lower dose intensity than in studies for PTCL. > The optimal tolerable starting dose and schedule for pralatrexate in patients with CTCL is 15 mg/m 2 qwk for 3/4 wk:
-Overall response rate: 61% for doses ≥15 mg/m 2 -Dose escalation was allowed in patients with stable disease or who showed a progressive response. -Expansion cohort is enrolling 20 additional patients at this dose and schedule (NCT00554827).
Faculty Comments
DR VOSE: Pralatrexate is a folate inhibitor that has been mostly studied in PTCL. This study examined the activity of pralatrexate in refractory CTCL and showed activity without unexpected toxicity. This is a potential agent in CTCL also and is continuing to be studied in combinations as well.
DR FOSS:
This was a dose and schedule determination study of pralatrexate in patients with refractory CTCL. The study demonstrates good activity in these patients, with an overall response rate of 61 percent for doses greater than or equal to 15 mg/m 2 for three of four weeks. The toxicity profile is similar to what has been seen in patients with PTCL. The dose and schedule moving forward in Phase II is 15 mg/m 2 weekly for three out of four weeks.
